GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Anthem Biosciences Ltd

Anthem Biosciences: Credit Rating Upgraded to [ICRA]AA(Stable)

RATING ▲ Positive Development LOW RISK
📅 Filed on BSE: 03 Jul 2026, 12:35 PM IST  ·  BSE ID: 618585d6-c7f7-4eb2-9892-caa0d02a7c28
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's creditworthiness has been improved by a rating agency, meaning it's seen as a more reliable borrower.
🤖 AI Summary
  • Anthem Biosciences' credit rating upgraded by ICRA to [ICRA]AA(Stable).
  • Long-term fund-based working capital rated Rs. 175.00 Crores.
  • Outlook revised from Positive to Stable across key credit instruments.
  • Multiple fund-based and unallocated facilities affected by rating action.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Total Rated Amount
275.50 Rs. Crores
Long Term/Short Term – Fund Based – Working Capital
175.00 Rs. Crores
Long Term – Fund Based – Term Loan
67.50 Rs. Crores
Short Term – Non-Fund based-others
10.00 Rs. Crores
Long Term/ Short Term – Unallocated
23.00 Rs. Crores
🏢 How This Affects the Company
📈
Business Impact
An improved credit rating can enhance the company's ability to secure future financing and potentially at more favorable terms.
💰
Financial Impact
The upgraded rating may lead to reduced borrowing costs and improved liquidity, strengthening the company's financial position.
⚠️
Risk Impact
A higher credit rating generally signifies lower financial risk for the company.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders regarding this credit rating update.
👤
Who Is Affected
All shareholders are indirectly affected as the company's improved creditworthiness can positively influence its financial stability and operational efficiency.
🔍
Management Signal
The upgrade signals management's success in improving the company's financial health and risk profile, leading to better credit standing.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
ICRA's annual surveillance review for rated instruments.
Company's future debt issuance plans and terms.
Subsequent financial results disclosures by the company.
LOW RISK Credit rating upgrade signifies reduced financial risk.
💡 Investor Takeaway
Anthem Biosciences' credit rating was upgraded by ICRA to [ICRA]AA(Stable) for instruments totaling Rs. 275.50 Crores, with the outlook revised from Positive to Stable.
⚖️ Strengths & Concerns

✅ Positives

  • Long-term/short-term fund-based working capital rated Rs. 175.00 Crores upgraded to [ICRA]AA(Stable).
  • Multiple credit instruments reaffirmed and upgraded, reflecting enhanced financial standing.
❓ Frequently Asked Questions
What is Anthem Biosciences' revised credit rating?
Anthem Biosciences' long-term and short-term fund-based working capital facilities have been upgraded to [ICRA]AA (Stable) by ICRA.
What is the total value of credit facilities with revised ratings?
The total value of credit facilities that have undergone rating revisions is Rs. 275.50 Crores.
What was the previous credit rating and outlook for Anthem Biosciences?
The previous rating was [ICRA]AA- (Positive), and the outlook has been revised from Positive to Stable.
Which instruments received the rating upgrade?
Instruments including Working Capital (Rs. 175.00 Cr), Term Loan (Rs. 67.50 Cr), and Unallocated (Rs. 23.00 Cr) received the upgrade.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.